Clinical Trials Logo

Unresectable Breast Cancer clinical trials

View clinical trials related to Unresectable Breast Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05945732 Recruiting - Clinical trials for Metastatic Breast Cancer

DESTINY Breast Respond HER2-low Europe

Start date: October 24, 2023
Phase:
Study type: Observational

Trastuzumab deruxtecan (T-DXd) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.